NCT05722977View on ClinicalTrials.gov

Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 2, 2023

Primary Completion Date

February 2, 2026

Study Completion Date

February 2, 2027

Conditions
Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
Interventions
DRUG

Surufatinib + envafolimab

Surufatinib: oral, fix dose 250mg, once a day; Envafolimab: subcutaneous injection, fix dose 300mg, once every three weeks

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER